Azitra pivots to cosmetics and biotech tools after $10.5M funding

The company, known for its precision dermatology research, is leveraging its microbial engineering platform to launch ATR-COSF, a recombinant filaggrin protein program targeting the skincare market. By repurposing technology originally designed to treat ichthyosis vulgaris, Azitra aims to enter the multi-billion dollar sector for anti-aging and skin hydration products, with human studies expected to conclude by late 2026.

Beyond skincare, Azitra is utilizing genetic engineering technologies licensed from The Fred Hutchinson Cancer Center to produce specialized proteins like TEV protease and T7 RNA polymerase. These tools, essential for mRNA vaccine assembly and research, address a market segment estimated at $1 billion. To support these new initiatives, the company is pausing enrollment in its ATR-12 Netherton syndrome trial to preserve capital. Meanwhile, the clinical development of ATR-04, a candidate for chemotherapy-associated skin rashes, will continue with the support of the MD Anderson Cancer Center.